Multicenter Real-World Study on Effectiveness and Early Discontinuation Predictors in Patients With Non-small Cell Lung Cancer Receiving Nivolumab

Abstract Background Real-world (RW) evidence on nivolumab in pretreated patients with non-small cell lung cancer (NSCLC) by matching data from administrative health flows (AHFs) and clinical records (CRs) may close the gap between pivotal trials and clinical practice. Methods This multicenter RW study aims at investigating median time to treatment discontinuation (mTTD), overall survival (mOS) of nivolumab in pretreated patients with NSCLC both from AHF and CR; clinical-pathological features predictive of early treatment discontinuation (etd), budget impact (BI), and cost-effectiveness analysis were investigated; mOS in patients receiving nivolumab and docetaxel was assessed. Results Overall, 237 patients with NSCLC treated with nivolumab were identified from AHFs; mTTD and mOS were 4.2 and 9.8 months, respectively; 141 (59%) received at least 6 treatment cycles, 96 (41%) received < 6 (etd). Median overall survival in patients with and without etd were 3.3 and 19.6 months, respectively (P < .0001). Higher number, longer duration, and higher cost of hospitalizations were observed in etd cases. Clinical records were available for 162 patients treated with nivolumab (cohort 1) and 83 with docetaxel (cohort 2). Median time to treatment discontinuation was 4.8 and 2.6 months, respectively (P < .0001); risk of death was significantly higher in cohort 2 or cohort 1 with etd compared with cohort 1 without etd (P < .0001). Predictors of etd were body mass index <25, Eastern Cooperative Oncology Group performance status >1, neutrophile-to-lymphocyte ratio >2.91, and concomitant treatment with antibiotics and glucocorticoids. The incremental cost-effectiveness ratio of nivolumab was 3323.64 euros ($3757.37) in all patients and 2805.75 euros ($3171.47) for patients without etd. Finally, the BI gap (real-theoretical) was 857 188 euros ($969 050.18). Conclusion We defined predictors and prognostic-economic impact of nivolumab in etd patients.

[1]  Xingliang Huang,et al.  Impact of corticosteroid use on outcomes of non–small‐cell lung cancer patients treated with immune checkpoint inhibitors: A systematic review and meta‐analysis , 2021, Journal of clinical pharmacy and therapeutics.

[2]  C. Molife,et al.  Data Integration to Improve Real-world Health Outcomes Research for Non–Small Cell Lung Cancer in the United States: Descriptive and Qualitative Exploration , 2020, JMIR cancer.

[3]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[4]  Shan Jia,et al.  Effect of antibiotic use on the efficacy of nivolumab in the treatment of advanced/metastatic non-small cell lung cancer: A meta-analysis , 2021, Open medicine.

[5]  Graham Roberts.  Real‐life data , 2020, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[6]  P. Conte,et al.  Real world data in the era of Immune Checkpoint Inhibitors (ICIs): Increasing evidence and future applications in lung cancer. , 2020, Cancer treatment reviews.

[7]  B. Asselain,et al.  Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS study , 2020, Oncoimmunology.

[8]  G. Metro,et al.  Immune checkpoints inhibitors rechallenge in non-small-cell lung cancer: different scenarios with different solutions? , 2019, Lung cancer management.

[9]  J. Penrod,et al.  Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: A national data base analysis. , 2019, Lung cancer.

[10]  L. Landi,et al.  Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer. , 2019, European journal of cancer.

[11]  J. Emile,et al.  Role of antibiotic use, plasma citrulline and blood microbiome in advanced non-small cell lung cancer patients treated with nivolumab , 2019, Journal of Immunotherapy for Cancer.

[12]  K. Naoki,et al.  Activity of Nivolumab and Utility of Neutrophil-to-Lymphocyte Ratio as a Predictive Biomarker for Advanced Non-Small-Cell Lung Cancer: A Prospective Observational Study. , 2019, Clinical lung cancer.

[13]  A. Chella,et al.  Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population. , 2019, The oncologist.

[14]  W. Mackillop,et al.  Real-world data: towards achieving the achievable in cancer care , 2019, Nature Reviews Clinical Oncology.

[15]  Rebecca A Miksad,et al.  Real-World Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval. , 2018, The oncologist.

[16]  J. Duarte,et al.  Real-world data from the Portuguese Nivolumab Expanded Access Program (EAP) in previously treated Non Small Cell Lung Cancer (NSCLC). , 2019, Pulmonology.

[17]  N. Pennell,et al.  Early Use of Systemic Corticosteroids in Patients with Advanced NSCLC Treated with Nivolumab , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[18]  A. Tafreshi,et al.  Pembrolizumab plus Chemotherapy for Squamous Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[19]  G. Corrao,et al.  Building reliable evidence from real-world data: Needs, methods, cautiousness and recommendations. , 2018, Pulmonary pharmacology & therapeutics.

[20]  E. Skovlund,et al.  The use of real-world data in cancer drug development. , 2018, European journal of cancer.

[21]  S. Banerji,et al.  Targeting the PD-1/PD-L1 axis for the treatment of non-small-cell lung cancer. , 2018, Current oncology.

[22]  E. Vasile,et al.  Italian Nivolumab Expanded Access Program in Nonsquamous Non–Small Cell Lung Cancer Patients: Results in Never‐Smokers and EGFR‐Mutant Patients , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[23]  L. Zitvogel,et al.  Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  M. Quintela,et al.  Real world data of nivolumab for previously treated non-small cell lung cancer patients: a Galician lung cancer group clinical experience. , 2018, Translational lung cancer research.

[25]  V. Adamo,et al.  Baseline neutrophilia, derived neutrophil‐to‐lymphocyte ratio (dNLR), platelet‐to‐lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel , 2018, Journal of cellular physiology.

[26]  S. Novello,et al.  Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[27]  O. Merimsky,et al.  Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data. , 2017, Lung cancer.

[28]  Jocelyn Gal,et al.  Optimizing drug development in oncology by clinical trial simulation: Why and how? , 2017, Briefings Bioinform..

[29]  M. Thomeer,et al.  Does nivolumab for progressed metastatic lung cancer fulfill its promises? An efficacy and safety analysis in 20 general hospitals. , 2018, Lung cancer.

[30]  Young Hak Kim,et al.  Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non-Small Cell Lung Cancer Treated with Nivolumab. , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[31]  C. Langer,et al.  Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. , 2017, Lung cancer.

[32]  Å. Helland,et al.  Real-world data on nivolumab treatment of non-small cell lung cancer , 2017, Acta oncologica.

[33]  J. Svensson,et al.  Assessing the value of cancer treatments from real world data—Issues, empirical examples and lessons learnt , 2017 .

[34]  S. Peters,et al.  OA03.05 Analysis of Early Survival in Patients with Advanced Non-Squamous NSCLC Treated with Nivolumab vs Docetaxel in CheckMate 057 , 2017 .

[35]  R. Califf,et al.  Real-World Evidence - What Is It and What Can It Tell Us? , 2016, The New England journal of medicine.

[36]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[37]  P. Mazzanti,et al.  Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: Recent insights and future challenges. , 2016, Cancer treatment reviews.

[38]  S Senan,et al.  Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[39]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[40]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[41]  Françoise Meunier,et al.  How can innovative forms of clinical research contribute to deliver affordable cancer care in an evolving health care environment? , 2013, European journal of cancer.